What the label describes as glutathione may in practice be partially spent material
The Fire That Never Goes Out (Chronic Neuroinflammation) Microglia, the brain's immune cells, shift to a pro-inflammatory M1 phenotype to clear debris
This is why, despite the exciting research, I do not currently offer BPC-157 injections or oral peptide supplements in my clinical practice
Similar to GLP-1(7-37), exenatide also acts as an agonist for GLP-1(7-37), but shows resistance to DPP-4 degradation and has a lower renal clearance rate in human, making exenatide the first successfully developed GLP-1 drug [6]
Its discouraging. In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight up to 50 pounds or more in many cases
This structural mismatch between BPC-157s biology and standard drug development pathways has contributed to the slow pace of clinical trial development, though it has not diminished scientific interest in the compound